New immunotherapy combo shows promise for Tough-to-Treat lymphoma
NCT ID NCT05464329
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing whether adding the immunotherapy drug mosunetuzumab to standard chemotherapy can safely treat aggressive B-cell lymphoma that has come back or not responded to treatment. About 24 adults will receive either DHAX or ICE chemotherapy plus mosunetuzumab. The main goal is to check for side effects, but researchers will also look at how many patients achieve complete remission.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Mosunetuzumab (an immunotherapy drug) combined with standard chemotherapy (DHAX or ICE)
- What this could lead to
- If successful, this could point toward a more effective treatment option for people with aggressive B-cell lymphoma that has come back or not responded to prior therapy.
- What could go wrong
- This is a very early (Phase 1) and small (24 participants) trial focused mainly on safety, not proof of effectiveness. The combination may cause significant side effects and may not work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA GRADE 3B are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat lymphomas
- Can a simple blood test spot lymphoma earlier?
- What happens years after CAR-T therapy? a study aims to find out
- Can a targeted drug boost standard chemo for an aggressive lymphoma?
- Can a single shot build a cancer army inside the body?
- Liver-Friendly lymphoma treatment? new drug dosing study offers hope